|135.95|| -1.62 / -1.18%|
Edwards Lifesciences Corp. engages in the patient-focused medical innovations for heart disease and critical care monitoring. It operates through the following geographical segments: United States, Europe, Japan, and Rest of the World. Its products are categorized into three areas: Surgical Heart Valve Therapy, Transcatheter Heart Valves, and Critical Care. The Surgical Heart Valve Therapy portfolio includes tissue heart valves and heart valve repair products for the surgical replacement or repair of a patient's heart valve. The portfolio also includes a diverse line of cardiac surgery systems used during minimally invasive surgical procedures, and cannulae, embolic protection devices and other products used during cardiopulmonary bypass. The Transcatheter Heart Valves portfolio includes technologies designed to treat heart valve disease using catheter-based approaches as opposed to open surgical techniques. Its portfolio includes technologies designed for nonsurgical replacement of heart valves. The Critical Care portfolio products hemodynamic monitoring systems used to measure a patient's heart function and fluid status in surgical and intensive care settings. The company was founded by Miles Lowell Edwards in 1958 and is headquartered in Irvine, CA..
|Michael A. Mussallem||Chairman & Chief Executive Officer|
|Scott B. Ullem||Chief Financial Officer & Vice President|
|Stanton J. Rowe||Chief Scientific Officer & VP-Advanced Technology|
|John P. McGrath||Vice President-Quality, Regulatory & Clinical|
|Aimee S. Weisner||Vice President & General Counsel|